Read more >
Beam Therapeutics is a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases.
BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023 First Patient Dosing in BEAM-201 Trial in Patients with T-ALL/T-LL Expected by Mid-2023 Regulatory Submissions Planned for BEAM-301 by Late
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, Jan.
Data from ESCAPE-1 and ESCAPE-2 Approaches to Be Presented During Poster Sessions at the 64th ASH Annual Meeting and Exposition CAMBRIDGE, Mass., Dec. 10, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base